Autologous Bone Marrow transplantation - Blog Science Connections

More documents

Recommendations

Info

SESSION I - LEUKEMIA A. ACUTE LEUKEMIA - AML
Page 1: Autologous Bone Marrow transplantat
Page 5 and 6: AUTOLOGOUS BONE MARROW TRANSPLANTAT
Page 7 and 8: Contents Preface xxi Acknowledgment
Page 9 and 10: High Dose Etoposide, Melphalan, Tot
Page 11 and 12: High-Dose Therapy and Autologous Bo
Page 13 and 14: Autologous Bone Marrow Transplantat
Page 15 and 16: Breast Tumor Cell Detection in Marr
Page 17 and 18: High Dose Chemo-Radiotherapy with B
Page 19 and 20: The Use of Recombinant Human Granul
Page 21: Session VIII - Further Developments
Page 25: Acknowledgments Publication of thes
Page 30 and 31: 4 CBV and ABMT for AML in CR1 remis
Page 32 and 33: 6 CBV and ABMT for AML in CR1 Table
Page 34 and 35: 8 CBV and ABMT for AML in CR1 full
Page 36 and 37: 10 CBV and ABMT for AML in CR1 wher
Page 38 and 39: 12 CBV and ABMT for AML in CRI 16.
Page 40 and 41: 14 Mafosfamide Purging in Acute Leu
Page 42 and 43: 16 Ma{osfamide Purging in Acute Leu
Page 48 and 49: 22 Timing of BMT for ANL Table 1. R
Page 50 and 51: 24 Timing of BMT for ANL 'SURVIVAL'
Page 52 and 53: 26 Timing of BMT for ANL (AML): Two
Page 54 and 55: 28 Timing of Bone Marrow Transplant
Page 56 and 57: 30 Merocyanine-540 and Mafosfamide
Page 58 and 59: 32 Merocyanine-540 and Mafosfamide
Page 61 and 62: Sensitivity of Leukemic Progenitors
Page 63 and 64: Sensitivity of Leukemic Progenitors
Page 65: Sensitivity of Leukemic Progenitors
Page 68 and 69: 42 ABMT for Consolidation of AML/AL
Page 76 and 77:
50 ABMT for Consolidation of AML/AL
Page 78 and 79:
52 ABMT for Consolidation of AML/AL
Page 81 and 82:
Hematopoietic Progenitor Selection
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Acute Leukemia - AML (Purging) 61 B
Page 89 and 90:
Acute Leukemia - AML ( Pur ging ) 6
Page 91:
Acute Leukemia - AML (Purging) 65 8
Page 94 and 95:
68 4HC/VCR Chemopurge BCNU/etoposid
Page 96 and 97:
70 4 HC/VCR Chemopurge Table 3. Rem
Page 98 and 99:
72 4HC/VCR Chemopurge 7. Vellekoop
Page 100 and 101:
74 Autologous BMT for ANLL by the J
Page 102 and 103:
76 Autologous BMT for ANLL Thirty-f
Page 104 and 105:
78 Autologous BMT for ANLL ACKNOWLE
Page 106 and 107:
80 Clinical Value of Auto BMT Dr. B
Page 108 and 109:
82 BAVC and ABMT in AML Patients 20
Page 110 and 111:
84 BAVC and ABMT in AML Patients ta
Page 112 and 113:
86 BAVC and AB MT in AML Patients 5
Page 114 and 115:
88 ABMT in Advanced ALL PATIENTS AN
Page 116 and 117:
90 ABMT in Advanced ALL patients ar
Page 119 and 120:
Autograft for AML 93 THE STATUS OF
Page 121 and 122:
Autograft for AML 95 post-ABMT. The
Page 123 and 124:
Autograft for AML 97 Regimen by the
Page 125:
Autograft for AML 99 2. Stewart P,
Page 128 and 129:
102 Etoposide, Melphalan, TBI and A
Page 130 and 131:
104 Etoposide, Melphalan, TBI and A
Page 133 and 134:
In Vitro/In Vivo Treatment of Leuke
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
BU/CY in BMT 113 HIGH-DOSE BUSULFAN
Page 141 and 142:
BU/CY in BMT 115 transplanted in fi
Page 143 and 144:
BU/CY in BUT 117 BU CY PREP REGIMEN
Page 145 and 146:
Double AML Transplants 119 BLOOMSBU
Page 147 and 148:
Double AML Transplants 121 Table 1.
Page 149 and 150:
Double AML Transplants 123 Event Fr
Page 151 and 152:
Double Transplants 125 DOUBLE UNPUR
Page 153 and 154:
id > •rl > U 3 CO •O c id 4) CO
Page 155 and 156:
Double Transplants 129 Discussion T
Page 157 and 158:
Double Transplants 131 Three patien
Page 159:
Double Transplants 133 Hickman RD,
Page 162 and 163:
136 Autologous vs. Allogeneic Trans
Page 165 and 166:
ABMT vs. Chemotherapy in High Risk
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Marrow Transplantation for ALL 145
Page 173 and 174:
Page 175:
Page 178 and 179:
152 ABMT Italian Study for Childhoo
Page 180 and 181:
154 ABMT Italian Study for Childhoo
Page 182 and 183:
756 Autologous Transplant for ALL T
Page 184 and 185:
158 Autologous Transplant for ALL T
Page 186 and 187:
160 Autologous Transplant for ALL 6
Page 188 and 189:
162 ABMT in ALL Sanofi Recherche, M
Page 190 and 191:
164 ABMT in ALL Leukaemia free surv
Page 192 and 193:
166 ABMT in ALL CONCLUSIONS - No ad
Page 194 and 195:
168 ABMT in ALL marrow was purged b
Page 197 and 198:
B43/CD19 PAP IT 171 B43/CD19-PAP IS
Page 199 and 200:
B43/CD19 PAP IT 173 immunotherapy.
Page 201 and 202:
B43/CD19 PAP IT 175 Specifically, B
Page 203 and 204:
B43/CD19 PAP IT 177 Table 2. Anti-L
Page 205 and 206:
Detection of Minimal Residual Disea
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Autologous BMT vs. Chemotherapy 187
Page 215 and 216:
Autologous BMT vs. Chemotherapy 189
Page 217 and 218:
Autologous vs. Allogeneic Transplan
Page 219 and 220:
Timing & Conditioning Regimens 193
Page 221 and 222:
Timing & Conditioning Regimens 195
Page 223:
SESSION II - LYMPHOMA
Page 226 and 227:
•P fi 0) •rl •P id Ol » +>
Page 228 and 229:
202 Purging with Anti-B Cell MoAb a
Page 230 and 231:
Xi •P •rl TJ ¿£ O O O CD —
Page 232 and 233:
206 Purging with Anti-B Cell MoAb a
Page 234 and 235:
208 Front Line Chemotherapy Regimen
Page 236 and 237:
Z 4- o N. 00 to O 00 to H— LTt to
Page 238 and 239:
Page 240 and 241:
Page 243 and 244:
Optimal Timing for ABMT in Non-Hodg
Page 245 and 246:
Page 247 and 248:
Page 249:
Page 252 and 253:
226 ABMT in NHL and HD — Timing o
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
232 The Role of Intensive Chemother
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 267 and 268:
Optimal Timing for Intermediate/Hig
Page 269 and 270:
Page 271:
Page 274 and 275:
248 BMT for Lymphoblastic Lymphoma
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
254 High Dose Therapy for Multiple
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
262 Hodgkin's Disease, ABMT after J
Page 290 and 291:
264 Hodgkin's Disease, ABMT and wer
Page 292 and 293:
266 Hodgkin's Disease, ABMT Candida
Page 295 and 296:
Timing of ABMT in Hodgkin's Disease
Page 297 and 298:
Page 299:
Page 302 and 303:
276 Timing of CBV and Autologous BM
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 311 and 312:
High Dose Chemotherapy Regimens for
Page 313 and 314:
Page 315 and 316:
Page 317:
Page 320 and 321:
294 Optimal Timing for Lymphoblasti
Page 323 and 324:
Optimal Timing for Hodgkin's 297 Di
Page 325 and 326:
BMT Preparative Regimens 299 IS THE
Page 327 and 328:
BMT Preparative Regimens 301 import
Page 329:
BMT Preparative Regimens 303 Table
Page 332 and 333:
306 Conditioning for AuBMT in NHL n
Page 334 and 335:
308 Conditioning for AuBMT in NHL T
Page 336 and 337:
310 Conditioning for AuBMT in NHL t
Page 338 and 339:
312 Escalating Dose CBV in Lymphoma
Page 340 and 341:
314 Escalating Dose CBV in Lymphoma
Page 343 and 344:
High Dose Chemotherapy with ABMT in
Page 345 and 346:
E -o m +> rt •H +> m Pi *M O m o
Page 347 and 348:
Page 349 and 350:
Page 351:
Page 354 and 355:
328 ABMT in Low Grade NHL ABMT in R
Page 356 and 357:
330 ABMT in Low Grade NHL ACKNOWLED
Page 358 and 359:
332 Purging and Relapse in BL PATIE
Page 360 and 361:
JZ s u in s 0) DC I a L. CD a +4 CO
Page 362 and 363:
336 Purging and Relapse in BL high
Page 364 and 365:
338 Purging and Relapse in BL 6. Ph
Page 366 and 367:
340 Detection of MRD by PCR crossov
Page 368 and 369:
342 Detection of MRD by PCR Figure
Page 371 and 372:
Conditioning Regimens in Lymphoma 3
Page 373 and 374:
Page 375:
Page 379 and 380:
Detection of Disease & Purging in L
Page 381:
SESSION III - SOLID TUMORS A. BREAS
Page 384 and 385:
358 ABMT as Intensification in Brea
Page 386 and 387:
360 ABMT as Intensification in Brea
Page 389 and 390:
Breast Cancer: Autologous Bone Marr
Page 391 and 392:
Breast Cancer: Autologous Bone Marr
Page 393 and 394:
High Dose Chemotherapy in Breast Ca
Page 395 and 396:
High Dose Chemotherapy in Breast Ca
Page 397 and 398:
High Dose Consolidation in Breast C
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
STAMP Studies in Breast Cancer 377
Page 405 and 406:
STAMP Studies in Breast Cancer 379
Page 408 and 409:
382 STAMP Studies in Breast Cancer
Page 411 and 412:
Solid Tumors I: Breast 385 Discussi
Page 413 and 414:
Solid Tumors I: Breast 387 study; p
Page 415 and 416:
Dose Intensification for the Treatm
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423:
Page 426 and 427:
400 High-Dose Intensification for B
Page 428 and 429:
402 High-Dose Intensification for B
Page 431 and 432:
ABMT and Hematopoietic Recovery in
Page 433 and 434:
Page 435 and 436:
Page 437:
SESSION III - SOLID TUMORS B. MINIM
Page 440 and 441:
414 Bone Marrow Metastases in Small
Page 442 and 443:
416 Borte Marrow Metastases in Smal
Page 444 and 445:
418 Bone Marrow Metastases in Small
Page 447 and 448:
Occult Tumor in Bone Marrow 421 REC
Page 449 and 450:
Occult Tumor in Bone Marrow 423 Tab
Page 451:
Occult Tumor in Bone Marrow 425 Dal
Page 454 and 455:
428 Breast Tumor Cell Detection Bon
Page 456 and 457:
430 Breast Tumor Cell Detection In
Page 458 and 459:
432 Breast Cancer have ours. His pi
Page 461:
SESSION III - SOLID TUMORS C. GLIOM
Page 464 and 465:
438 Various Treatments in Gliomas 3
Page 466 and 467:
440 Various Treatments in Gliomas a
Page 468 and 469:
442 Various Treatments in Gliomas T
Page 470 and 471:
444 Various Treatments in Gliomas G
Page 472 and 473:
446 Various Treatments in Gliomas H
Page 475 and 476:
ABMT in Pediatric Brain Tumors 449
Page 477 and 478:
Page 479 and 480:
Page 481:
Page 484 and 485:
458 Adjuvant High-Dose BCNU and BMT
Page 486 and 487:
460 Adjuvant High-Dose BCNU and BMT
Page 489 and 490:
Gliomas 463 Discussion 3 - Session
Page 491 and 492:
Gliomas 465 Dr. August: I personall
Page 493:
SESSION III - SOLID TUMORS D. TESTI
Page 496 and 497:
470 ABMT for Germ Cell Tumors PATIE
Page 498 and 499:
472 ABMT for Germ Cell Tumors Table
Page 500 and 501:
474 ABMT for Germ Cell Tumors 3) Th
Page 502 and 503:
476 ABMT for Germ Cell Tumors In Di
Page 504 and 505:
478 Massive Chemotherapy in NSGCT T
Page 506 and 507:
480 Massive Chemotherapy in NSGCT R
Page 508 and 509:
482 Massive Chemotherapy in NSGCT T
Page 510 and 511:
484 Massive Chemotherapy in NSGCT S
Page 512 and 513:
486 Massive Chemotherapy in NSGCT s
Page 514 and 515:
488 CBDCA/VP-16 in Germ-Cell Cancer
Page 516 and 517:
490 CBDCA/VP-16 in Germ-Cell Cancer
Page 519 and 520:
Testicular Cancer 493 Discussion 4
Page 521 and 522:
Testicular Cancer 495 Dr. Frei: Our
Page 523:
SESSION III - SOLID TUMORS E. MELAN
Page 526 and 527:
500 ABMT for Advanced Melanoma Marr
Page 528 and 529:
502 ABMT for Advanced Melanoma in p
Page 530 and 531:
504 ABMT for Advanced Melanoma Tabl
Page 532 and 533:
506 ABMT for Advanced Melanoma 16.
Page 535 and 536:
HDM and ABMT in Ovarian Carcinomas
Page 537 and 538:
Page 539 and 540:
Page 541:
Page 545 and 546:
High Dose Carboplatin 519 A PHASE I
Page 547 and 548:
High Dose Carboplatin 521 Figure 1.
Page 549:
High Dose Carboplatin 523 Table 3.
Page 552 and 553:
526 G.I. Tumors we actually demonst
Page 555 and 556:
Treatment of Metastatic Neuroblasto
Page 557 and 558:
Page 559 and 560:
Page 561 and 562:
Page 563 and 564:
Page 565 and 566:
Page 567:
Page 570 and 571:
544 BMT in Neuroblastoma Table 1. M
Page 572 and 573:
546 BMT in Neuroblastoma The influe
Page 574 and 575:
548 BMT in Neuroblastoma 3. Philip
Page 576 and 577:
550 ABMT in Neuroblastoma MATERIALS
Page 578 and 579:
552 ABMT in Neuroblastoma GM ranges
Page 580 and 581:
LH S3 pq < o O ¡8 •O V -p 0) a 0
Page 582 and 583:
556 ABMT in Neuroblastoma DISCUSSIO
Page 585 and 586:
Myeloablative Treatment for Childre
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
AutoBMT for Neuroblastoma at CHOP 5
Page 595 and 596:
Page 597 and 598:
Page 599:
Page 602 and 603:
576 Neuroblastoma with Intensive Th
Page 604 and 605:
Page 606 and 607:
Page 608 and 609:
Page 611 and 612:
Neuroblastoma 585 Discussion 1 - Se
Page 613 and 614:
Neuroblastoma 587 Dr. Favrot: The p
Page 615 and 616:
Neuroblastoma 589 Because if it is,
Page 617:
SESSION IV - PEDIATRIC TUMORS B. SA
Page 620 and 621:
594 Ewing's Sarcoma Phase II Metast
Page 622 and 623:
Page 624 and 625:
Page 627 and 628:
ABMT in Wilms' Tumor: An EBMT Surve
Page 629 and 630:
41 — ci «i ra eu § C0 > O CA >
Page 631 and 632:
Page 633:
Page 636 and 637:
610 Consolidation Therapy in Metast
Page 638 and 639:
Page 640 and 641:
Page 643 and 644:
ABMT in Pediatric Sarcomas 617 HIGH
Page 645 and 646:
ABMT in Pediatric Sarcomas 619 Tabl
Page 647 and 648:
Sarcoma 621 Discussion 2 - Session
Page 649:
SESSION V - GROWTH FACTORS
Page 652 and 653:
626 Effects of IL-1 on Hematopoiesi
Page 654 and 655:
628 Effects of IL-1 on Hematopoiesi
Page 657 and 658:
hGM-CSF After Marrow Transplantatio
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
IL-1 as Protection from Toxic Effec
Page 665 and 666:
Page 667 and 668:
Page 669:
Page 672 and 673:
646 Growth Factor Therapy in Primat
Page 674 and 675:
Page 676 and 677:
Page 678 and 679:
652 Differences Between Normal and
Page 680 and 681:
Page 682 and 683:
Page 684 and 685:
658 rHuGM-CSF in Autologous Bone Ma
Page 686 and 687:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
Page 695 and 696:
Growth Factors 669 Discussion 1 - S
Page 697:
Growth Factors 671 Dr. Gale: There
Page 700 and 701:
674 Growth Factors Dr. Frei: Just o
Page 703 and 704:
GM-CSF and PB Progenitor Cells 677
Page 705 and 706:
Page 707 and 708:
Page 709:
Page 712 and 713:
686 Peripheral Blood CFU-GM and BFU
Page 714 and 715:
Page 716 and 717:
Page 718 and 719:
Page 720 and 721:
694 Occult Tumor in Apheresis Harve
Page 722 and 723:
696 Occult Tumor in Apheresis Harve
Page 724 and 725:
698 Stern Cell Collection and Toxic
Page 726 and 727:
700 Stem Cell Collection and Toxici
Page 729 and 730:
Lymphoma and PSCT 703 RESPONSE OF P
Page 731 and 732:
Lymphoma and PSCT 705 ACTUAMAL mOBA
Page 733 and 734:
PBSC Transplants in Solid Tumors 70
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Autologous Blood Stem Cell Transpla
Page 741 and 742:
Ç o to i— cil DC *-> CU in Z} O
Page 743:
Autologous Blood Stem Cell Transpla
Page 746 and 747:
720 Peripheral Blood Stem Cells ANL
Page 748 and 749:
722 Peripheral Blood Stem Cells REF
Page 750 and 751:
724 Myeloablative Treatments in Hae
Page 752 and 753:
Page 754 and 755:
Page 756 and 757:
Page 759 and 760:
Peripheral Blood Stem Cells 733 Dis
Page 761 and 762:
Peripheral Blood Stem Cells 735 of
Page 763 and 764:
Peripheral Blood Stem Cells 737 Dr.
Page 765 and 766:
Peripheral Blood Stem Cells 739 wit
Page 767:
SESSION VII - SUPPORTIVE CARE
Page 770 and 771:
744 Treatment of Cytomegalovirus Pn
Page 772 and 773:
746 Treatment of Cytomegalovirus Pn
Page 774 and 775:
748 Viral Infection in BMT infectio
Page 776 and 777:
750 Viral Infection in BMT VZV duri
Page 779 and 780:
IV+PO Ig in ABMT 753 INTRAVENOUS AN
Page 781 and 782:
IV+PO Ig in ABMT 755 regimen was mo
Page 783 and 784:
IV+PO Ig in ABMT 757 malignancies (
Page 785 and 786:
Supportive Care 759 Discussion 1 -
Page 787:
SESSION VIII - FURTHER DEVELOPMENTS
Page 790 and 791:
764 Merocyanine 540 wild type count
Page 792 and 793:
766 Merocyanine 540 Also, it is not
Page 795 and 796:
Purging with Aldophosphamide Acetá
Page 797 and 798:
Page 799 and 800:
Page 801 and 802:
Page 803:
Page 806 and 807:
780 Further Developments in Purging
Page 808 and 809:
782 Further Developments in Purging
Page 811 and 812:
Further Developments in Purging 785
Page 813 and 814:
Page 815 and 816:
Page 817:
SESSION IX - INTERNATIONAL PROTOCOL
Page 820 and 821:
794 PARMA International Protocol Th
Page 822 and 823:
796 PARMA International Protocol re
Page 824 and 825:
798 PARMA International Protocol 17
Page 826 and 827:
800 Double ABMT in Advanced Neurobl
Page 828 and 829:
Page 830 and 831:
Page 833 and 834:
General Discussion 807 General Disc
Page 835:
General Discussion 809 a very good
Page 839 and 840:
Autotransplants: Acute Leukemia 813
Page 841 and 842:
Page 843:
Page 846 and 847:
820 Pierre Andolenko, Centre Hospit
Page 848 and 849:
822 E. Berman, Memorial Sloan-Kette
Page 850 and 851:
824 Glenn J. Bubley, Division of He
Page 852 and 853:
826 M. Colvin also known as O. Mich
Page 854 and 855:
828 Giorgio Dini, Unita Trapianto d
Page 856 and 857:
830 Mary Flaherty, Dana Farber Canc
Page 858 and 859:
832 Alain Gouyette, Service de Phar
Page 860 and 861:
834 Leonard J. Horwitz, Department
Page 862 and 863:
836 David Lamaster, Department of R
Page 864 and 865:
838 Thomas J. Mac Vittie, Experimen
Page 866 and 867:
840 Alessandra Micozzi, Hematology,
Page 868 and 869:
842 Mark Owen, Department of Hemato
Page 870 and 871:
844 C. Patrick Reynolds, Department
Page 872 and 873:
846 Elizabeth J. Shpall, Bone Marro
Page 874 and 875:
848 Simon Sutcliffe, Toronto Genera
Page 876 and 877:
850 R. Warrell, Memorial Sloan-Kett
show all

Autologous Bone Marrow transplantation - Blog Science Connections

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?